Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Healthy
Interventions: Ixekizumab; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Infections, Bacterial
Interventions: GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
Interventions: AL001, Placebo; Drug · Other
Lead sponsor: Alzamend Neuro, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Atrophic Vaginitis
Interventions: Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 44
States / cities: Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more

Conditions: Bioavailability
Interventions: PF-07321332/ritonavir, PF-07321332; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Sunscreening Agents
Interventions: BAY987516, SPF Control; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Healthy Volunteers
Interventions: Maribavir; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 Reference formulation, GSK1265744 New formulation 1, GSK1265744 New formulation 2; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV Infections
Interventions: DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 2,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: Melanoma
Interventions: Relatlimab, Nivolumab, Relatlimab + Nivolumab; Drug
Lead sponsor: John Kirkwood; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Influenza
Interventions: Influenza Virus Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 11 Months
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 6
States / cities: Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 3 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania

Conditions: Xerostomia
Interventions: Biotene mouthwash, Bottled mineral water; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Macular Edema, Retina Vein Occlusion
Interventions: GB-102; Drug
Lead sponsor: Graybug Vision; Industry
Eligibility: 21 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Phoenix, Arizona • Savannah, Georgia • Louisville, Kentucky + 3 more

Conditions: Healthy Subjects
Interventions: PF-06882961, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Participants
Interventions: Ad35.RSV.FA2, Ad26.RSV.FA2, Placebo; Biological · Drug
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Subjects
Interventions: Experimental paracetamol formulation, Marketed paracetamol, Higher dose marketed paracetamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Influenza
Interventions: High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 792 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Milford, Connecticut • Coral Gables, Florida • Wichita, Kansas + 6 more

Conditions: Influenza
Interventions: Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions: PVX-108, Placebo; Biological
Lead sponsor: Aravax Pty Ltd; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 8
States / cities: Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more

Conditions: Paget's Disease of the Bone, Hypocalcemia
Interventions: Reclast (ZOL446, zoledronic acid), Calcium, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Tucson, Arizona • Gainesville, Georgia + 6 more

Conditions: Healthy
Interventions: LY3074828; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia or Schizoaffective
Interventions: Lumateperone Capsule, Lumateperone LAI; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Los Alamitos, California • Atlanta, Georgia • Marlton, New Jersey

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
Interventions: Liothyronine, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study of Ixekizumab in Healthy Participants

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

Sun Protection Factor Assay (339/2016)

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mouth Subjects

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®

A Study of Two Different Formulations of LY3074828 in Healthy Participants

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

Developing Oral LT3 Therapy for Heart Failure - HFrEF